| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | TAK-715 | GDSC1000 | pan-cancer | AAC | -0.0036 | 0.9 |
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | 0.0042 | 0.9 |
| mRNA | LBW242 | CCLE | pan-cancer | AAC | -0.0056 | 0.9 |
| mRNA | BRD-A94377914 | CTRPv2 | pan-cancer | AAC | -0.0045 | 0.9 |
| mRNA | MS-275 | FIMM | pan-cancer | AAC | 0.013 | 0.9 |
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | -0.0057 | 0.9 |
| mRNA | BRD-K26531177 | CTRPv2 | pan-cancer | AAC | -0.0036 | 0.9 |
| mRNA | N9-isopropylolomoucine | CTRPv2 | pan-cancer | AAC | 0.0034 | 0.9 |
| mRNA | BRD9647 | CTRPv2 | pan-cancer | AAC | 0.0035 | 0.9 |
| mRNA | BRD-K33199242 | CTRPv2 | pan-cancer | AAC | 0.0035 | 0.9 |